NASDAQ:ICCC ImmuCell Q4 2023 Earnings Report $5.50 +0.01 (+0.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History ImmuCell EPS ResultsActual EPS-$0.15Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuCell Revenue ResultsActual Revenue$5.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuCell Announcement DetailsQuarterQ4 2023Date2/27/2024TimeN/AConference Call DateWednesday, February 28, 2024Conference Call Time9:00AM ETUpcoming EarningsImmuCell's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by ImmuCell Q4 2023 Earnings Call TranscriptProvided by QuartrFebruary 28, 2024 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:00Good morning, and welcome to the ImmuCell Corporation Reports 4th Quarter and Year Ended December 31, 2023, Unaudited Financial Results Conference Call. Today, all participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask your questions. I would now like to turn the conference over to Mr. Joe Diaz with Lytham Partners. Operator00:00:23Please go ahead, sir. Speaker 100:00:25Thank you, Chris. Good morning and welcome to all. As Chris indicated, my name is Joe Diaz. I'm with Lytham Partners. We're the Investor Relations consulting firm for ImmuCell. Speaker 100:00:37I thank all of you for joining us today to discuss the unaudited financial results for the quarter and the year ended December 31, 2023. I would like to preface this discussion today with a caution regarding forward looking statements. Listeners are reminded that statements made by management during the course of this call include forward looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward looking statements or the Safe Harbor statement provided in the press release that the company filed last night, along with the company's other periodic filings with the SEC. Speaker 100:01:45Information discussed on today's call speaks only as of today, Wednesday, February 28, 2024. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation, after which we will open the call for your questions. Speaker 100:02:31Michael? Speaker 200:02:33Thanks, Joe, and good morning, everyone. Let me open by saying the hard truth straight up. 2023 was an extremely difficult year for us. The contamination events that plagued our production process were harsh and expensive. Growth is challenging and we are growing. Speaker 200:02:49The good news is that we believe we have moved into 2024 in a much improved state. The investigation into and the remediation of these contamination events taught us a lot. It is relatively simple to run our to run at lower production rates for the 30 years between 1991, the original USDA approval date of First Defense, and 2021. The contamination events we suffered during 2022 2023 were largely the result of our processing more milk than ever before in order to meet increasing customer demand. As we enter 2024, we believe that we have much improved processes and controls in place from the farms through liquid processing. Speaker 200:03:35I would like to speak about 2 financial disclosures that I think help demonstrate this critical turning point for our business. First, excuse me, while sales were down 6% year over year, they were up 30% during the Q4 of 2023 compared to the Q4 of 2022. This improvement is largely the result of increased production output. The production level we reached during the final 2 months of the year would annualize to about 26.8 $1,000,000 in sales value, which equates to an average quarterly production of about $6,700,000 Our objective is to meet or exceed this level going forward. 2nd, EBITDA earnings before interest, taxes, depreciation and amortization decreased by $2,900,000 during 2020 3 compared to 2022, but EBITDA during the Q4 of 2023 improved by $657,000 in comparison to the Q4 of 2022. Speaker 200:04:41So that's a big picture. With regards to the other financial results, last minute's press release reports no change to our product sales results that were first reported on January 8. The press release also provides the full unaudited P and L results and some unaudited summary balance sheet data. I will not take our time on this call to review all those numbers in detail, but I would like to discuss a high level overview. When we compare the year ended December 31, 'twenty three to the prior year, the $3,300,000 increase in our net loss was largely caused by the $3,800,000 decrease in gross margin. Speaker 200:05:17The lower gross margin in 2023 was largely the result of contamination scrap and a lot of fixed costs being spread over lower total sales as we slowed down production output to remediate the production problems. As a result of all this, cash is tight. In response, we have frozen certain capital expenditure investments for the time being and we recently secured an extension of our $1,000,000 line of credit until September of 2025. We have been driven by data as we resolve this temporary production problem. All production batches are and always have been routinely tested by our quality control team at the beginning, middle and end of the production process to ensure that no out of specification product ever gets to market. Speaker 200:06:05Improvements made throughout the production process are allowing us to come back into full production. We believe that the operational improvements implemented will help us run more effectively at a higher output level going forward. We have worked incredibly hard to address these challenges. To be successful, we must avoid future significant contamination events and equipment breakdowns and operate with good production yields. Based on our responses and progress, I am optimistic about what we can do in the coming quarters. Speaker 200:06:36Despite this significant diversion of our resources, we made our 3rd submission of the CMC technical section for RETAIN to the FDA in August. This type of submission is typically subject to a 6 month review by the FDA. However, the FDA notified us in late October that they had refused to review our August submission because of a misunderstanding about where and by whom we intend to have our drug product aseptically formulated and filled. Our understanding is that the FDA believed that our plan was to bring those services in house, which we might do down the road post approval rather than to continue to have these services provided by our contract manufacturer, which is what we are doing currently. In response to this notification from the FDA, we were forced to refile our submission in November. Speaker 200:07:24We are in communication with the FDA to resolve this unfortunate miscommunication, but if we fail to reach a compromise, the expected response date for their review could be delayed until as late as May 2024, which is 6 months from the November resubmission date. Regardless, we remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market with a novel alternative to traditional antibiotics with 0 milk discard and 0 meat withhold claims. Lastly, I encourage you to review the press release that we filed last night. Also, please have a look at our corporate presentation slide deck. I believe it provides a very good summary of our business strategy and objectives, as well as our current financial results. Speaker 200:08:10A February update was just posted to our website last night. See the Investors section on our website and click on Corporate Presentation or contact us for a copy. We plan to file our full annual report on Form 10 ks for the year ended December 31, 2023 around the end of March. With that said, I'll be happy to take your questions. Let's have the operator open up the lines please. Operator00:08:38Thank Today's first question comes from Frank Gasker, a Private Investor. Please go ahead, sir. Speaker 300:09:29The inspections, are all the inspection facilities completed? Speaker 200:09:36I would answer that Frank. Good morning Frank. Yes. In process, I see no issues, but it is an ongoing process at both our site and our contract manufacturers. So we're making progress and responding to their action, but it's ongoing. Speaker 200:09:52So far, so good. Speaker 300:09:54How about the backlog? You made no comment. I know that's a little iffy because of the circumstances. Speaker 200:10:04Yes, it's interesting. It's still very large. So we've done 2 things that might have resulted in a decrease in backlog. We have increased sales, increased production and sales out our door. And we also did have an increase in selling price about 8% back in November. Speaker 200:10:28But however relevant or not relevant, those two things are, the fact is the backlog pretty stable, pretty strong. So honestly, Frank, I will just be focused on production. And you know what, the backlog is, I guess, a good sign at this point. But certainly, the objective is we got to clear it. We got to clear it. Speaker 200:10:50But it remains strong. It's a good problem to have, but it's a problem. We're going to clear it. But great demand. It's a very interesting to watch. Speaker 200:10:58I would have thought it might have been leveling down by now. Speaker 300:11:04As far as your work in progress or process for your inventory, have you had anything in the Q4 that would affect future revenues or sales? Frank, when Speaker 200:11:28you say anything, do you mean like any further contaminations? Speaker 300:11:33Yes. Yes. Speaker 200:11:35Yes, no. 4th quarter was really super strong. I mentioned in my comments, no significant contaminations. I don't think we'll ever be in a state where we'll never have a contamination, but that full quarter worked. We were we go back to September for the last contamination event. Speaker 300:11:57I guess what I'm asking is, like in the Q3, you had issues that affected 4th quarter. Is there anything in the Q4 that's going to affect the 1st quarter? Speaker 200:12:11No, that disclosure was current. That's our most recent contamination challenge at September, but it does affect October shipments. Speaker 300:12:21Okay. That sounds great. Speaker 200:12:23All right, great. Speaker 300:12:26I guess the only issue that I have remaining would be the statement in regards to working with the FDA as to when the start of the 3rd submission, Is that known or not known at the present time? Speaker 200:12:54It is I mean, I have to put my mind around they're going to stick to their schedule. That doesn't mean I think it's fair, but their schedule is May and we're continuing to talk about how could you possibly advance that a little bit. But I guess I do know what 6 months from the resubmission is, resubmission November and 6 months later is May. So that's why we had to sort of say by the end of May, It's tough. I think there should be some compromise and I think it should be something in between. Speaker 200:13:28The original expectation was February. So the range was February to May. But at this point, I have to just be realistic and say it's out of my hands. They have the power and it may not be till May. Speaker 300:13:44And given that approval could be as late as May and then the 2 months prior, are we in a position to as far as cash to begin that sales and marketing? Speaker 200:14:13Oh, yes. Oh, yes. I mean, but keep in mind those disclosures we made what we call a controlled launch and we're not going to be blitzing the market with a huge advertising and sales and marketing budget. It's but yes, no, I think your timeline is right and the cash is there for that. If CMC is complete by May, if you add 60 days to that for the what's called the administrative review, May goes to July, then you have a month or 2 for labeling and just organizing. Speaker 200:14:46So it's there July, August, September, we actually initiate that controlled launch. But that is not a there's not a cash burden on that, that scares me at all. Speaker 300:15:00Okay, great. Okay. Mike, thanks again for taking my questions. That's all I have. Yes, great. Speaker 300:15:07Thank you. Speaker 400:15:20And at this time, we Operator00:15:21are showing no further questioners in the queue. And this does conclude our question and answer session. I would now like to turn the conference back over to Joe Diaz. Speaker 200:15:29Hey, Chris. Why are you still there? Maybe could we grab Sean? I think he can. Operator00:15:33Yes. Thank you so much, sir. And the next question comes from Mr. Sean Kirkewood with SRK Capital. Please proceed. Speaker 300:15:42Hi, thanks. Sorry for jumping in late Speaker 400:15:46there. Can you hear me, Mike? Speaker 200:15:47Yes. Go ahead, Sean. Thanks. Speaker 400:15:50So I had a question about the cash. So on the balance sheet today, there's roughly $1,000,000 Speaker 200:15:59it looks? Speaker 400:16:01Correct. Are you anticipating that the company is going to need cash throughout the year or is the Q1 going to start the cash flow? Speaker 200:16:14Well, yes, that is a thin capitalization. That's a thin cash balance. We can manage it. We're frugal. We know how to do it. Speaker 200:16:21I mentioned the CapEx freezes. I don't like freezing CapEx. CapEx investments are important for the future, but we have to deal with the present. That line of credit news is important to me. That's nice flexibility. Speaker 200:16:34I don't like to lean on that, but I'd like to have that back pocket safety. And yes, the main thing, the most important thing is continue what we saw there towards the end of the Q4 into the first quarter that First Defense cash flows this business and at these higher rates of output production output, 24 looks a lot different than 23. So we would expect those numbers to be released on April 8. We were in the habit of which I would continue that top line only press release early after the end of the quarter. So let me confirm my projections on April 8. Speaker 300:17:18Okay. Yes, I mean, just from looking at it, Speaker 400:17:22it seems like the business should do well this quarter. Can you speak Speaker 200:17:27a little bit to the mastitis segment? Speaker 300:17:33A bit about maybe the losses that are they supposed Speaker 400:17:36to be in line kind of with historical losses this year in that segment? Speaker 200:17:42So you mean like the health economic loss impact to the dairy producer or Speaker 400:17:50So within the retained segment of your business, I think historically, it's been around $4,000,000 a year of losses in that segment. Should we expect something around that number this year? Speaker 200:18:04Okay. You're not talking about the market, you're talking about our product development? Right. That's correct. Yes. Speaker 200:18:10No, I did specifically call out CapEx investments, pauses or freezes, but we're also super careful on that retained spend. So we do I think you're picking up, Beth, is it Note 17? Either way, that segment notes, I put our team on the spot here. I think it's 17 if my memory is any good, but it's the segment note. We wanted to be able to answer your question very specifically as we go through this launch to look at the First Defense business, the Retain business and the other. Speaker 200:18:48So all I guess long winded to say, yes, we're the bulk of their production for this launch and for this the bulk of the regulatory costs and investments related to retain are reducing as we complete that process. So less than 23 as we go into 24 when we look at that product development expense line. Okay. And that's just part of that cash management, got to do it. That's a stretch. Speaker 200:19:23But good, I'm glad we're not in the middle of the heavy spend on the regulatory submission process. At the same time, we're looking at this $1,000,000 in cash. The big spend is behind us. Good. Well, it sounds good. Speaker 200:19:37It sounds like the Speaker 400:19:38year is very optimistic. So thank you. Speaker 200:19:42Hey, thanks for checking, Sean. Good deal. Speaker 300:19:44Thanks. Take care. Operator00:19:49And this does now conclude our question and answer session. I would now like to turn the conference back over to Mr. Joe Diaz for any closing remarks. Speaker 200:20:04Hey, Chris, we might have lost Joe's line there, but let me just jump in on his behalf. All we wanted to say at this point was thank you for participating in today's call and we look forward to talking with you again to review the results for the Q1 ended March 31, 2024, towards the end of the week of May 6, 2024. Operator00:20:28And thank you. This now does conclude our conference. Thank you for attending today's presentation and you may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallImmuCell Q4 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Annual report(10-K) ImmuCell Earnings HeadlinesTop Stock Reports for Netflix, SAP & ShellApril 17 at 11:50 AM | uk.finance.yahoo.comImmuCell appoints new CFO to bolster growth strategyApril 9, 2025 | uk.investing.comMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.April 20, 2025 | Behind the Markets (Ad)ImmuCell Corporation: ImmuCell Hires Chief Financial OfficerApril 9, 2025 | finanznachrichten.deImmucell reports preliminary Q1 revenue $8.1M vs. $7.3M last yearApril 9, 2025 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025April 8, 2025 | markets.businessinsider.comSee More ImmuCell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email. Email Address About ImmuCellImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.View ImmuCell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:00Good morning, and welcome to the ImmuCell Corporation Reports 4th Quarter and Year Ended December 31, 2023, Unaudited Financial Results Conference Call. Today, all participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask your questions. I would now like to turn the conference over to Mr. Joe Diaz with Lytham Partners. Operator00:00:23Please go ahead, sir. Speaker 100:00:25Thank you, Chris. Good morning and welcome to all. As Chris indicated, my name is Joe Diaz. I'm with Lytham Partners. We're the Investor Relations consulting firm for ImmuCell. Speaker 100:00:37I thank all of you for joining us today to discuss the unaudited financial results for the quarter and the year ended December 31, 2023. I would like to preface this discussion today with a caution regarding forward looking statements. Listeners are reminded that statements made by management during the course of this call include forward looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward looking statements or the Safe Harbor statement provided in the press release that the company filed last night, along with the company's other periodic filings with the SEC. Speaker 100:01:45Information discussed on today's call speaks only as of today, Wednesday, February 28, 2024. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation, after which we will open the call for your questions. Speaker 100:02:31Michael? Speaker 200:02:33Thanks, Joe, and good morning, everyone. Let me open by saying the hard truth straight up. 2023 was an extremely difficult year for us. The contamination events that plagued our production process were harsh and expensive. Growth is challenging and we are growing. Speaker 200:02:49The good news is that we believe we have moved into 2024 in a much improved state. The investigation into and the remediation of these contamination events taught us a lot. It is relatively simple to run our to run at lower production rates for the 30 years between 1991, the original USDA approval date of First Defense, and 2021. The contamination events we suffered during 2022 2023 were largely the result of our processing more milk than ever before in order to meet increasing customer demand. As we enter 2024, we believe that we have much improved processes and controls in place from the farms through liquid processing. Speaker 200:03:35I would like to speak about 2 financial disclosures that I think help demonstrate this critical turning point for our business. First, excuse me, while sales were down 6% year over year, they were up 30% during the Q4 of 2023 compared to the Q4 of 2022. This improvement is largely the result of increased production output. The production level we reached during the final 2 months of the year would annualize to about 26.8 $1,000,000 in sales value, which equates to an average quarterly production of about $6,700,000 Our objective is to meet or exceed this level going forward. 2nd, EBITDA earnings before interest, taxes, depreciation and amortization decreased by $2,900,000 during 2020 3 compared to 2022, but EBITDA during the Q4 of 2023 improved by $657,000 in comparison to the Q4 of 2022. Speaker 200:04:41So that's a big picture. With regards to the other financial results, last minute's press release reports no change to our product sales results that were first reported on January 8. The press release also provides the full unaudited P and L results and some unaudited summary balance sheet data. I will not take our time on this call to review all those numbers in detail, but I would like to discuss a high level overview. When we compare the year ended December 31, 'twenty three to the prior year, the $3,300,000 increase in our net loss was largely caused by the $3,800,000 decrease in gross margin. Speaker 200:05:17The lower gross margin in 2023 was largely the result of contamination scrap and a lot of fixed costs being spread over lower total sales as we slowed down production output to remediate the production problems. As a result of all this, cash is tight. In response, we have frozen certain capital expenditure investments for the time being and we recently secured an extension of our $1,000,000 line of credit until September of 2025. We have been driven by data as we resolve this temporary production problem. All production batches are and always have been routinely tested by our quality control team at the beginning, middle and end of the production process to ensure that no out of specification product ever gets to market. Speaker 200:06:05Improvements made throughout the production process are allowing us to come back into full production. We believe that the operational improvements implemented will help us run more effectively at a higher output level going forward. We have worked incredibly hard to address these challenges. To be successful, we must avoid future significant contamination events and equipment breakdowns and operate with good production yields. Based on our responses and progress, I am optimistic about what we can do in the coming quarters. Speaker 200:06:36Despite this significant diversion of our resources, we made our 3rd submission of the CMC technical section for RETAIN to the FDA in August. This type of submission is typically subject to a 6 month review by the FDA. However, the FDA notified us in late October that they had refused to review our August submission because of a misunderstanding about where and by whom we intend to have our drug product aseptically formulated and filled. Our understanding is that the FDA believed that our plan was to bring those services in house, which we might do down the road post approval rather than to continue to have these services provided by our contract manufacturer, which is what we are doing currently. In response to this notification from the FDA, we were forced to refile our submission in November. Speaker 200:07:24We are in communication with the FDA to resolve this unfortunate miscommunication, but if we fail to reach a compromise, the expected response date for their review could be delayed until as late as May 2024, which is 6 months from the November resubmission date. Regardless, we remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market with a novel alternative to traditional antibiotics with 0 milk discard and 0 meat withhold claims. Lastly, I encourage you to review the press release that we filed last night. Also, please have a look at our corporate presentation slide deck. I believe it provides a very good summary of our business strategy and objectives, as well as our current financial results. Speaker 200:08:10A February update was just posted to our website last night. See the Investors section on our website and click on Corporate Presentation or contact us for a copy. We plan to file our full annual report on Form 10 ks for the year ended December 31, 2023 around the end of March. With that said, I'll be happy to take your questions. Let's have the operator open up the lines please. Operator00:08:38Thank Today's first question comes from Frank Gasker, a Private Investor. Please go ahead, sir. Speaker 300:09:29The inspections, are all the inspection facilities completed? Speaker 200:09:36I would answer that Frank. Good morning Frank. Yes. In process, I see no issues, but it is an ongoing process at both our site and our contract manufacturers. So we're making progress and responding to their action, but it's ongoing. Speaker 200:09:52So far, so good. Speaker 300:09:54How about the backlog? You made no comment. I know that's a little iffy because of the circumstances. Speaker 200:10:04Yes, it's interesting. It's still very large. So we've done 2 things that might have resulted in a decrease in backlog. We have increased sales, increased production and sales out our door. And we also did have an increase in selling price about 8% back in November. Speaker 200:10:28But however relevant or not relevant, those two things are, the fact is the backlog pretty stable, pretty strong. So honestly, Frank, I will just be focused on production. And you know what, the backlog is, I guess, a good sign at this point. But certainly, the objective is we got to clear it. We got to clear it. Speaker 200:10:50But it remains strong. It's a good problem to have, but it's a problem. We're going to clear it. But great demand. It's a very interesting to watch. Speaker 200:10:58I would have thought it might have been leveling down by now. Speaker 300:11:04As far as your work in progress or process for your inventory, have you had anything in the Q4 that would affect future revenues or sales? Frank, when Speaker 200:11:28you say anything, do you mean like any further contaminations? Speaker 300:11:33Yes. Yes. Speaker 200:11:35Yes, no. 4th quarter was really super strong. I mentioned in my comments, no significant contaminations. I don't think we'll ever be in a state where we'll never have a contamination, but that full quarter worked. We were we go back to September for the last contamination event. Speaker 300:11:57I guess what I'm asking is, like in the Q3, you had issues that affected 4th quarter. Is there anything in the Q4 that's going to affect the 1st quarter? Speaker 200:12:11No, that disclosure was current. That's our most recent contamination challenge at September, but it does affect October shipments. Speaker 300:12:21Okay. That sounds great. Speaker 200:12:23All right, great. Speaker 300:12:26I guess the only issue that I have remaining would be the statement in regards to working with the FDA as to when the start of the 3rd submission, Is that known or not known at the present time? Speaker 200:12:54It is I mean, I have to put my mind around they're going to stick to their schedule. That doesn't mean I think it's fair, but their schedule is May and we're continuing to talk about how could you possibly advance that a little bit. But I guess I do know what 6 months from the resubmission is, resubmission November and 6 months later is May. So that's why we had to sort of say by the end of May, It's tough. I think there should be some compromise and I think it should be something in between. Speaker 200:13:28The original expectation was February. So the range was February to May. But at this point, I have to just be realistic and say it's out of my hands. They have the power and it may not be till May. Speaker 300:13:44And given that approval could be as late as May and then the 2 months prior, are we in a position to as far as cash to begin that sales and marketing? Speaker 200:14:13Oh, yes. Oh, yes. I mean, but keep in mind those disclosures we made what we call a controlled launch and we're not going to be blitzing the market with a huge advertising and sales and marketing budget. It's but yes, no, I think your timeline is right and the cash is there for that. If CMC is complete by May, if you add 60 days to that for the what's called the administrative review, May goes to July, then you have a month or 2 for labeling and just organizing. Speaker 200:14:46So it's there July, August, September, we actually initiate that controlled launch. But that is not a there's not a cash burden on that, that scares me at all. Speaker 300:15:00Okay, great. Okay. Mike, thanks again for taking my questions. That's all I have. Yes, great. Speaker 300:15:07Thank you. Speaker 400:15:20And at this time, we Operator00:15:21are showing no further questioners in the queue. And this does conclude our question and answer session. I would now like to turn the conference back over to Joe Diaz. Speaker 200:15:29Hey, Chris. Why are you still there? Maybe could we grab Sean? I think he can. Operator00:15:33Yes. Thank you so much, sir. And the next question comes from Mr. Sean Kirkewood with SRK Capital. Please proceed. Speaker 300:15:42Hi, thanks. Sorry for jumping in late Speaker 400:15:46there. Can you hear me, Mike? Speaker 200:15:47Yes. Go ahead, Sean. Thanks. Speaker 400:15:50So I had a question about the cash. So on the balance sheet today, there's roughly $1,000,000 Speaker 200:15:59it looks? Speaker 400:16:01Correct. Are you anticipating that the company is going to need cash throughout the year or is the Q1 going to start the cash flow? Speaker 200:16:14Well, yes, that is a thin capitalization. That's a thin cash balance. We can manage it. We're frugal. We know how to do it. Speaker 200:16:21I mentioned the CapEx freezes. I don't like freezing CapEx. CapEx investments are important for the future, but we have to deal with the present. That line of credit news is important to me. That's nice flexibility. Speaker 200:16:34I don't like to lean on that, but I'd like to have that back pocket safety. And yes, the main thing, the most important thing is continue what we saw there towards the end of the Q4 into the first quarter that First Defense cash flows this business and at these higher rates of output production output, 24 looks a lot different than 23. So we would expect those numbers to be released on April 8. We were in the habit of which I would continue that top line only press release early after the end of the quarter. So let me confirm my projections on April 8. Speaker 300:17:18Okay. Yes, I mean, just from looking at it, Speaker 400:17:22it seems like the business should do well this quarter. Can you speak Speaker 200:17:27a little bit to the mastitis segment? Speaker 300:17:33A bit about maybe the losses that are they supposed Speaker 400:17:36to be in line kind of with historical losses this year in that segment? Speaker 200:17:42So you mean like the health economic loss impact to the dairy producer or Speaker 400:17:50So within the retained segment of your business, I think historically, it's been around $4,000,000 a year of losses in that segment. Should we expect something around that number this year? Speaker 200:18:04Okay. You're not talking about the market, you're talking about our product development? Right. That's correct. Yes. Speaker 200:18:10No, I did specifically call out CapEx investments, pauses or freezes, but we're also super careful on that retained spend. So we do I think you're picking up, Beth, is it Note 17? Either way, that segment notes, I put our team on the spot here. I think it's 17 if my memory is any good, but it's the segment note. We wanted to be able to answer your question very specifically as we go through this launch to look at the First Defense business, the Retain business and the other. Speaker 200:18:48So all I guess long winded to say, yes, we're the bulk of their production for this launch and for this the bulk of the regulatory costs and investments related to retain are reducing as we complete that process. So less than 23 as we go into 24 when we look at that product development expense line. Okay. And that's just part of that cash management, got to do it. That's a stretch. Speaker 200:19:23But good, I'm glad we're not in the middle of the heavy spend on the regulatory submission process. At the same time, we're looking at this $1,000,000 in cash. The big spend is behind us. Good. Well, it sounds good. Speaker 200:19:37It sounds like the Speaker 400:19:38year is very optimistic. So thank you. Speaker 200:19:42Hey, thanks for checking, Sean. Good deal. Speaker 300:19:44Thanks. Take care. Operator00:19:49And this does now conclude our question and answer session. I would now like to turn the conference back over to Mr. Joe Diaz for any closing remarks. Speaker 200:20:04Hey, Chris, we might have lost Joe's line there, but let me just jump in on his behalf. All we wanted to say at this point was thank you for participating in today's call and we look forward to talking with you again to review the results for the Q1 ended March 31, 2024, towards the end of the week of May 6, 2024. Operator00:20:28And thank you. This now does conclude our conference. Thank you for attending today's presentation and you may now disconnect.Read morePowered by